LGALS3BP and ovarian cancer: Subsequently, the top five candidate biomarkers, including LGALS3BP were validated by immunohistochemistry on TMAs (Tissue MicroArrays) and survival analyses in a large series of > 200 primary early stage ovarian cancer tissues.